Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Halneuron

Other · developed by Dogwood Therapeutics

Phase 2 Most advanced trial

DWTX Developer

1 Registered trials

What is Halneuron?

Halneuron is a subcutaneously injected agent studied in chemotherapy-induced neuropathic pain.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Other
Therapy area: Neurology
Developer: Dogwood Therapeutics Inc. (DWTX)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06848348	Phase 2	Chemotherapy Induced Neuropathic Pain	Active not recruiting	DWTX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Chemotherapy Induced Neuropathic PainChemotherapy Induced PainChemotherapy Induced Pain Neuropathy

Sources

ClinicalTrials.gov NCT06848348

Updated Oct 11, 2026. Something wrong or missing? Report it on the DWTX page.

Follow DWTX, the company behind Halneuron

See DWTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

DWTX catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z